Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 3, 2005, Pages 284-292

  Grabar, Sophie ^a,b   Moing, Vincent Le ^c   Goujard, Cécile ^d   Egger, Matthias ^e   Leport, Catherine ^f   Kazatchkine, Michel D ^g   Weiss, Laurence ^g   Costagliola, Dominique ^a  

^a INSERM   (France)

^b Université Paris V ^*  (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITY OF BERN   (Switzerland)

^f BICHAT HOSPITAL   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antiretroviral therapy; CD4 lymphocyte count; HIV infection; Prognosis; Treatment outcome; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATABASES, FACTUAL; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS;

EID: 21544475508     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000160925.33935.72     Document Type: Article

References (30)

1. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
2. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res Hum Retroviruses. 2000; 16:1123-1133.
3. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA. 1999;282:2220-2226.
4. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14:141-149.
5. Miller V, Sabin CA, Phillips AN, et al. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS. 2000;14:2129-2136.
6. National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://AIDSinfo. nih.gov. Accessed 2004.
7. Committee for Proprietary Medicinal Products. Note for Guidance on the Clinical Development of Medicinal Products for Treatment of HIV Infection. London: EMEA; 2003.
8. US Food and Drug Administration. Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements. Clinical Considerations for Accelerated and Traditional Approval. US Food and Drug Administration; Rockville, MD, 2002.
9. d'Arminio Monforte A, Testori V, Adomi F, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS. 1999;13:1669-1676.
10. Grabar S, Moing VL, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000; 133:401-410.
11. Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis. 2001;183:1328-1335.
12. Chene G, Steme JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
13. Williams PL, Currier JS, Swindells S. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. AIDS. 1999;13:1035-1044.
14. Thiebaut R, Thiessard F, Merchadou LD, et al. Antiretroviral combination therapy and HIV infection. Long term follow up of patients under triple therapy is necessary. BMJ. 1998;317:887-888.
15. Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999; 29:1423-1430.
16. Kaufmann D, Pantaleo G, Sudre P, et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) [letter]. Lancet. 1998;351:723-724.
17. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998; 12:745-750.
18. Le Moing V, Chêne G, Masquelier B, et al. Definition of virological response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy [letter]. J Acquir Immune Defic Syndr. 2000;24:82-83.
19. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep. 1992; 41(RR-17):1-19.
20. Burnham K, Anderson D. Model selection and Inference. A Practical Information-Theoretic Approach. New York: Springer-Verlag; 1998.
21. The ART Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
22. Binquet C, Chene G, Jacqmin-Gadda H, et al. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. Am J Epidemiol. 2001;153:386-393.
23. Le Moing V, Thiebaut R, Chene G, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2002;185:471-480.
24. Abgrall S, Duval X, Joly V, et al. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis. 2003;37:1517-1526.
25. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362:2002-2011.
26. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-234.
27. Belec L, Piketty C, Si Mohamed A, et al. High levels of drug-resistant HIV variants in patients exhibiting increasing CD4 T cell counts despite virological failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis. 2000;181:1808-1812.
28. Duval X, Darmon S, Longuet P, et al. Evolution of protease and reverse transcriptase inhibitor-associated mutations in HIV-1 protease inhibitor-treated patients with persistent low viremia. Presented at: 10th Conference on Retroviruses and Opportunistic infections; 2003; Boston.
29. Palella FJ, Jr, Chmiel JS, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16:1617-1626.
30. Carried MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther. 2003;8:585-594.